HR Execs on the Move

bioMASON

www.biomason.com

 
We build with carbon the same way nature does. Our biocement® materials are healthier for us and the Planet.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

TECHNE CORP /MN/

TECHNE CORP /MN/ is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CymaBay

CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline.

Vidara Therapeutics

Vidara Therapeutics is a Alpharetta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BiomedAIliance

BiomedAIliance is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Avadim Technologies

Avadim Technologies Inc is a life sciences company that has developed a new class of life sciences solutions based on Pathogenesis Based Therapies (“PBTs”) which work to optimize the stratum corneum, integumentary functions and the associated reactive tissue. Our platform of therapies works to protect and support natural physiological functions of the outer barrier of the body, to super normalize it, supporting treatments within our three series of therapies for infection prevention, neuromuscular disorders and barrier repair. Our platform and technologies use a targeted topical delivery system, are non-toxic and are effective without the side effects of other remedy approaches. Initial acceptance in the U.S. clinical market of our first PBTs and our novel preventative approach, have shown both cost avoidance and superior effectiveness in addressing specific needs in healthcare. Avadim’s advanced therapeutic class of Pathogenesis Based Therapies is capable of unlocking pathways to address emerging gaps in global health.